This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

D-cycloserine Augmented CBT for Panic Disorder

This study is currently recruiting participants.
See Contacts and Locations
Verified November 2015 by University of Oxford
Medical Research Council
Information provided by (Responsible Party):
University of Oxford Identifier:
First received: September 3, 2012
Last updated: December 2, 2015
Last verified: November 2015
The purpose of this study is to determine whether d-cycloserine augments the clinical effects of exposure-based cognitive-behaviour therapy for panic disorder.

Condition Intervention Phase
Panic Disorder Drug: d-cycloserine Drug: placebo Behavioral: cognitive-behaviour therapy Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Effect of a Single-dose of D-cycloserine on the Basic Effects of Cognitive-behaviour Therapy for Panic Disorder - a Randomized Placebo-controlled Trial

Resource links provided by NLM:

Further study details as provided by University of Oxford:

Primary Outcome Measures:
  • self-reported and clinician-rated anxiety and depression measures [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • emotional information processing [ Time Frame: 1 day ]

Estimated Enrollment: 50
Study Start Date: October 2012
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: d-cycloserine
oral, capsule, 250 mg, once
Drug: d-cycloserine Behavioral: cognitive-behaviour therapy
Placebo Comparator: sugar pill
oral, capsule, once
Drug: placebo Behavioral: cognitive-behaviour therapy


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • clinical diagnosis of panic disorder
  • at least moderate agoraphobic avoidance

Exclusion Criteria:

  • psychoactive medication last 6 weeks
  • exposure-based cognitive-behaviour treatment for panic disorder and agoraphobia during last 3 months
  • female participant who is pregnant or breast-feeding
  • lifetime history of psychosis, bipolar disorder, alcohol, medication or drug abuse or dependence; current primary depressive disorder
  • lifetime history of epilepsy or other significant disease or disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01680107

Contact: Andrea Reinecke, PhD +44 (0)1865 226471

United Kingdom
Department of Psychiatry, University of Oxford Recruiting
Oxford, United Kingdom, OX37JX
Contact: Andrea Reinecke, PhD    +44 (0)1865 226471   
Principal Investigator: Andrea Reinecke, PhD         
Sponsors and Collaborators
University of Oxford
Medical Research Council
Principal Investigator: Andrea Reinecke, PhD University of Oxford
Study Director: Catherine Harmer, PhD University of Oxford
  More Information

Responsible Party: University of Oxford Identifier: NCT01680107     History of Changes
Other Study ID Numbers: MRC-01
2012-003191-39 ( EudraCT Number )
Study First Received: September 3, 2012
Last Updated: December 2, 2015

Keywords provided by University of Oxford:
d-cycloserine, cognitive-behaviour therapy, panic disorder

Additional relevant MeSH terms:
Panic Disorder
Pathologic Processes
Anxiety Disorders
Mental Disorders
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017